Table 1.
Baseline characteristics.
| Characteristics | Total (n = 217) |
|---|---|
| Age - years | |
| median | 67 |
| range | 30-90 |
| Age > 65 | 121 (55.8%) |
| Sex, n (%) | |
| Male | 151 (69.6%) |
| Female | 66 (30.4%) |
| Histological differentiation | |
| Well differentiation | 4 (1.8%) |
| Moderated differentiation | 74 (34.1%) |
| High differentiation | 116 (53.5%) |
| Signet ring cell | 18 (8.3%) |
| Other | 5 (2.3%) |
| Invasion depth | |
| T1 | 12 (5.5%) |
| T2 | 21 (9.7%) |
| T3 | 102 (47.0%) |
| T4 | 82 (37.8%) |
| Lymph node metastasis | |
| Negative | 46 (21.2%) |
| Positive | 171 (78.8%) |
| Lymphatic invasion | |
| Negative | 71 (32.7%) |
| Positive | 146 (67.3%) |
| Venous invasion | |
| Negative | 78 (35.9%) |
| Positive | 139 (64.1%) |
| Perineural invasion | |
| Negative | 88 (40.6%) |
| Positive | 129 (59.4%) |
| TNM stage | |
| II | 98 (45.2%) |
| III | 119 (54.8%) |
| Surgery | |
| Total gastrectomy | 75 (34.6%) |
| Subtotal gastrectomy | 142 (65.4%) |
| Adjuvant chemotherapy | |
| No | 33 (15.2%) |
| Yes | 184 (84.8%) |
| Adjuvant chemotherapy regimen | N=184(100%) |
| FL | 25 (13.6%) |
| S-1 | 84 (45.7%) |
| XELOX | 57 (31.0%) |
| FOLFOX | 4 (2.2%) |
| Other | 14 (7.6%) |
TNM: tumor-node-metastasis; FL: 5-fluorouracil and leucovorin; XELOX: capecitabine and oxaliplatin; FOLFOX: 5-fluorouracil, leucovorin, and oxaliplatin.